These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 26245702)
1. An update in treatment options for multiple myeloma in nontransplant eligible patients. Broijl A; Sonneveld P Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702 [TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. Ashjian E; Redic K J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345 [TBL] [Abstract][Full Text] [Related]
3. Emerging therapies in multiple myeloma. El-Amm J; Tabbara IA Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133 [TBL] [Abstract][Full Text] [Related]
4. [Management of multiple myeloma in the relapsed/refractory patient]. Tabayashi T Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851 [TBL] [Abstract][Full Text] [Related]
5. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Nijhof IS; van de Donk NWCJ; Zweegman S; Lokhorst HM Drugs; 2018 Jan; 78(1):19-37. PubMed ID: 29188449 [TBL] [Abstract][Full Text] [Related]
6. Current use of monoclonal antibodies in the treatment of multiple myeloma. Varga C; Maglio M; Ghobrial IM; Richardson PG Br J Haematol; 2018 May; 181(4):447-459. PubMed ID: 29696629 [TBL] [Abstract][Full Text] [Related]
7. Emerging biological insights and novel treatment strategies in multiple myeloma. Gentile M; Recchia AG; Mazzone C; Morabito F Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042 [TBL] [Abstract][Full Text] [Related]
8. Future agents and treatment directions in multiple myeloma. Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247 [TBL] [Abstract][Full Text] [Related]
12. Resistance to proteasome inhibitors and other targeted therapies in myeloma. Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460 [TBL] [Abstract][Full Text] [Related]
13. Elotuzumab as a novel anti-myeloma immunotherapy. Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269 [TBL] [Abstract][Full Text] [Related]
14. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945 [TBL] [Abstract][Full Text] [Related]
15. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. van de Donk NW; Lokhorst HM Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099 [TBL] [Abstract][Full Text] [Related]
16. A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. Cook G; Zweegman S; Mateos MV; Suzan F; Moreau P Crit Rev Oncol Hematol; 2018 Jan; 121():74-89. PubMed ID: 29279102 [TBL] [Abstract][Full Text] [Related]
17. Contemporary drug therapies for multiple myeloma. de la Puente P; Azab AK Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952 [TBL] [Abstract][Full Text] [Related]
18. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882 [TBL] [Abstract][Full Text] [Related]
19. How is patient care for multiple myeloma advancing? Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554 [TBL] [Abstract][Full Text] [Related]
20. New pharmacotherapy options for multiple myeloma. Mina R; Cerrato C; Bernardini A; Aghemo E; Palumbo A Expert Opin Pharmacother; 2016; 17(2):181-92. PubMed ID: 26684262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]